Concepedia

Rakesh Kumar

RK

24

Publications

1.5K

Citations

18

H-Index

2002

Active since

Affiliations

AstraZeneca (United States)(Current)

The University of Texas MD Anderson Cancer Center

Sarah Cannon

Seoul National University Hospital

AstraZeneca (United Kingdom)

Rakesh Kumar is an author at AstraZeneca (United States) specializing in oncology, medicine, and radiation oncology.

ORCID

Top concepts

Publications per year

2002–2025

24

Publications

24

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients

Takuya Osada, Gabriel T. Chong, Robert Tansik et al. · Cancer Immunology Immunotherapy · 2008 · 304 citations · Full text

, , +11

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors

Rakesh Kumar, M-C Crouthamel, David H. Rominger et al. · British Journal of Cancer · 2009 · 218 citations · Full text

Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer

Charu Aggarwal, Roger B. Cohen, Matthew P. Morrow et al. · Clinical Cancer Research · 2018 · 138 citations · Full text

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

Benjamin Besse, Elvire Pons‐Tostivint, Keunchil Park et al. · Nature Medicine · 2024 · 102 citations · Full text

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial

Tina Cascone, Gozde Kar, Jonathan Spicer et al. · Cancer Discovery · 2023 · 101 citations · Full text

Rows per page

1–5 of 24